Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

At the peak of the COVID-19 pandemic, many vaccine skeptics turned to ivermectin, a medication proven to fight off parasitic ...

By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

Novavax's vaccine has been available since 2022 in the U.S. after the FDA granted its emergency use. "We look forward to ...

Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “We believe that our Biologics License ...

A person familiar with the situation told CNN that the FDA is seeking more data on the vaccine, which has been available under emergency use authorization since 2022. It was the first Covid-19 ...

A top FDA official directly intervened in an agency review of Novavax’s Covid-19 vaccine, pausing the approval process to ask for more data on the shot, according to four people familiar with ...